<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346461</url>
  </required_header>
  <id_info>
    <org_study_id>150068</org_study_id>
    <secondary_id>15-HG-0068</secondary_id>
    <nct_id>NCT02346461</nct_id>
  </id_info>
  <brief_title>An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy</brief_title>
  <official_title>An Open-Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Human Genome Research Institute (NHGRI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Patients with GNE myopathy have progressive muscle weakness and can have difficulty walking
      and decreased mobility. The disease is a rare genetic disorder that results from a gene
      mutation in a key step in the body's production of a sugar called sialic acid, (also called
      N-acetylneuraminic acid, Neu5Ac). Researchers think decreased sialic acid bound to muscle
      proteins may be the cause of muscle wasting in GNE myopathy. Researchers are testing the drug
      ManNAc which is a precursor in the production of sialic acid within cells. ManNAc is provided
      as a powder dissolved in water to be administered orally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GNE myopathy is a rare genetic (autosomal recessive) disorder that causes progressive
      skeletal muscle atrophy and weakness. The disease presents in young adults typically between
      the ages of 20 and 40 years, and includes foot drop and difficulty walking. The disease
      progresses to involve all skeletal muscles, eventually leading to the use of a wheelchair
      and, in some cases, dependence on a caregiver. The causative gene, GNE, encodes the
      rate-limiting enzyme in the biosynthesis of CMP-sialic acid. While the exact pathophysiology
      of GNE myopathy remains unknown, decreased sialic acid production and subsequent
      hyposialylation of muscle glycoproteins are thought to be key factors leading to muscle
      deterioration in GNE myopathy. This hypothesis is supported by prevention of disease after
      administration of oral N-acetyl-D-mannosamine (ManNAc) in mouse models of GNE myopathy. A
      first-in-human, Phase 1 single ascending dose study evaluated the safety, pharmacokinetics,
      and pharmacodynamics of a single dose of 3, 6, or 10 g of oral ManNAc in subjects with GNE
      myopathy (ClinicalTrials.gov NCT01634750; IND No.78,091). ManNAc was safe and well-tolerated
      in all subjects who participated in this study.

      In this Phase 2, open-label, single-center study ManNAc will be administered orally to 12
      subjects. The objectives of the study are to assess the long-term safety, tolerability,
      pharmacokinetics, and biochemical efficacy of oral ManNAc in GNE myopathy subjects. In the
      first phase of pharmacokinetic assessment, two cohorts of 6 subjects will receive ManNAc at
      doses of 3 g twice a day (6 g per day) or 6 g twice a day (12 g per day) for 7 days to assess
      safety and PK. In the second phase of the study, all subjects will receive treatment with
      ManNAc at a dose of 6 g twice daily (12 g per day) for the remainder of the study. The study
      was extended to include follow-up evaluations at 6, 12, 18, 24 and 30 months. During the 30
      month visit, PK of 4 g three times daily was assessed. Biochemical efficacy was assessed by
      change in the sialylation of proteins at 3 months compared to baseline. To evaluate the
      effect of ManNAc on clinical measures of GNE myopathy, a battery of clinical assessments was
      performed at every visit to identify clinical endpoints suitable for subsequent clinical
      trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2015</start_date>
  <completion_date type="Actual">November 15, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted)</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean area under the plasma ManNAc concentration-versus time curve from time 0 (dosing) to the time of last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of ManNAc (Baseline-adjusted)</measure>
    <time_frame>Day 7</time_frame>
    <description>The maximum (or peak) plasma ManNAc concentration that the drug achieves in the body after the drug has been administrated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Time to Cmax (Tmax) for ManNAc</measure>
    <time_frame>Day 7</time_frame>
    <description>The time taken to achieve the maximum observed plasma concentration for ManNAc .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t Â½) for ManNAc</measure>
    <time_frame>Day 7</time_frame>
    <description>The amount of time it takes for plasma ManNAc concentration to decline by half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Area Under the Curve (AUClast) of Plasma Neu5Ac (Baseline-adjusted)</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean area under the plasma Neu5Ac concentration-versus time curve from time 0 (dosing) to the time of last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Neu5Ac (Baseline-adjusted)</measure>
    <time_frame>Day 7</time_frame>
    <description>The maximum (or peak) plasma Neu5Ac concentration that the drug achieves in the body after the drug has been administrated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Time to Cmax (Tmax) for Neu5Ac</measure>
    <time_frame>Day 7</time_frame>
    <description>The time taken to achieve the maximum observed plasma concentration for Neu5Ac.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>GNE Myopathy</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ManNAc</intervention_name>
    <description>At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ManNAc</intervention_name>
    <description>At doses of 6 g twice daily (12 g per day).</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Subject is age 18-60 years, inclusive, and of either gender.

          -  Subject has a diagnosis of GNE myopathy based upon a consistent clinical course and
             identification of two GNE gene mutations.

          -  Subject must be willing to stop any treatment with ManNAc, sialic acid, intravenous
             immunoglobulin (IVIG), and/or other supplements containing sialic acid (e.g. St. John
             s wort, sialyllactose) 90 days prior to dosing and remain off such treatment for the
             duration of the trial.

          -  Subjects must have a body mass index (BMI) between 18 and 30 kg/m2, with a bodyweight
             of &gt;50 kg.

          -  Subjects must have 20-75% of predicted strength measured by QMA at baseline on at
             least one of the following: 1) ankle dorsiflexion, 2) knee flexion, 3) hip extension,
             4) grip, 5) elbow flexion, shoulder abduction

               -  20-75% of predicted strength measures by OMA at baseline, or

               -  If predicted muscle strength above 75%, a documented change of at least 10% per
                  year.

          -  Subject has the ability to travel to the NIH Clinical Center for admissions.

          -  Subject has an INR less than or equal to 1.5 and must have stopped warfarin and other
             anticoagulants 2 weeks prior and after muscle biopsy procedures. Aspirin and
             clopidogrel should be stopped 3 days and 5 days before the procedure, respectively.

          -  Subject must be able to comply with requirements of the protocol, including blood
             collection, drug administration, muscle MRI/MRS, muscle biopsy and muscle strength
             assessments.

          -  If a woman of reproductive age, subject must be willing to use an effective method of
             contraception for the duration of the trial.

          -  Subject must be able to provide informed consent.

        EXCLUSION CRITERIA:

          -  Subject had a clinical significant infection or medical illness 30 days prior to the
             first protocol visit.

          -  Subject has a psychiatric illness or neurological disease that would interfere with
             the ability to comply with the requirements of this protocol. This includes, but is
             not limited to, uncontrolled/untreated psychotic depression, bipolar disorder,
             schizophrenia, substance abuse or dependence, antisocial personality disorder, panic
             disorder, or behavioral problems, which interfere with effective communication.

          -  Subject has hepatic laboratory parameters (AST, ALT, GGTP) or renal laboratory
             parameters (creatinine, BUN) greater than 3 times the upper limit of normal.

          -  Subject has known adverse reactions to anesthetic or sedatives utilized for muscle
             biopsy.

          -  Subject is anemic (defined as Hematocrit &lt;30%) or has platelets &lt;100,000 or white
             blood cell count less than 3,000.

          -  Subject shows evidence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematological, metabolic, or gastrointestinal disease, or has a condition that
             requires immediate surgical intervention.

          -  Subject is pregnant or breastfeeding at any time during the study.

          -  Subject has received treatment with another investigational drug, investigational
             device, or approved therapy for investigational use less than 90 days prior to the
             first protocol visit.

          -  Subject has hypersensitivity to ManNAc or in the judgment of the investigator, has a
             condition that places the subject at increased risk for adverse effects.

          -  Subject has received ManNAc, sialic acid, intravenous immunoglobulin (IVIG), and/or
             other supplements containing sialic acid (e.g. St. John s wort, sialyllactose) less
             than 90 days prior to the first protocol visit.

          -  The presence of persistent diarrhea or malabsorption that could interfere with the
             subject s ability to absorb drugs or to tolerate ManNAc therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuria Carrillo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Human Genome Research Institute (NHGRI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 24, 2015</study_first_submitted>
  <study_first_submitted_qc>January 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <results_first_submitted>December 27, 2018</results_first_submitted>
  <results_first_submitted_qc>March 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Inclusion Body Myopathy (HIBM)</keyword>
  <keyword>Sialic Acid (N-acetylneuraminic acid, Neu5Ac)</keyword>
  <keyword>GNE Myopathy</keyword>
  <keyword>N-Acetyl-D-mannosamine (ManNAc)</keyword>
  <keyword>GNE Gene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Distal Myopathies</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02346461/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ManNAc: Cohort A</title>
          <description>Cohort A received oral ManNAc 3 g twice daily (6 g/day) for 7 days and, then were escalated to 6 g twice daily (12 g/day) for the remainder of the study.</description>
        </group>
        <group group_id="P2">
          <title>ManNAc: Cohort B</title>
          <description>Cohort B received oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ManNAc: Cohort A</title>
          <description>Cohort A received oral ManNAc 3 g twice daily (6 g/day) for 7 days and, then were escalated to 6 g twice daily (12 g/day) for the remainder of the study.</description>
        </group>
        <group group_id="B2">
          <title>ManNAc: Cohort B</title>
          <description>Cohort B received oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted)</title>
        <description>The mean area under the plasma ManNAc concentration-versus time curve from time 0 (dosing) to the time of last quantifiable concentration.</description>
        <time_frame>Day 7</time_frame>
        <population>All subjects received ManNAc</population>
        <group_list>
          <group group_id="O1">
            <title>ManNAc: Cohort A</title>
            <description>ManNAc 3 g twice daily (6 g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>ManNAc: Cohort B</title>
            <description>ManNAc 6 g twice daily (12 g/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted)</title>
          <description>The mean area under the plasma ManNAc concentration-versus time curve from time 0 (dosing) to the time of last quantifiable concentration.</description>
          <population>All subjects received ManNAc</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7461" spread="1776"/>
                    <measurement group_id="O2" value="9432" spread="2710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of ManNAc (Baseline-adjusted)</title>
        <description>The maximum (or peak) plasma ManNAc concentration that the drug achieves in the body after the drug has been administrated.</description>
        <time_frame>Day 7</time_frame>
        <population>All subjects received ManNAc</population>
        <group_list>
          <group group_id="O1">
            <title>ManNAc: Cohort A</title>
            <description>ManNAc 3 g twice daily (6 g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>ManNAc: Cohort B</title>
            <description>ManNAc 6 g twice daily (12 g/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of ManNAc (Baseline-adjusted)</title>
          <description>The maximum (or peak) plasma ManNAc concentration that the drug achieves in the body after the drug has been administrated.</description>
          <population>All subjects received ManNAc</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1588" spread="28.9"/>
                    <measurement group_id="O2" value="1774" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Time to Cmax (Tmax) for ManNAc</title>
        <description>The time taken to achieve the maximum observed plasma concentration for ManNAc .</description>
        <time_frame>Day 7</time_frame>
        <population>All subjects received ManNAc</population>
        <group_list>
          <group group_id="O1">
            <title>ManNAc: Cohort A</title>
            <description>ManNAc 3 g twice daily (6 g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>ManNAc: Cohort B</title>
            <description>ManNAc 6 g twice daily (12 g/day)</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Cmax (Tmax) for ManNAc</title>
          <description>The time taken to achieve the maximum observed plasma concentration for ManNAc .</description>
          <population>All subjects received ManNAc</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.4"/>
                    <measurement group_id="O2" value="2.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life (t Â½) for ManNAc</title>
        <description>The amount of time it takes for plasma ManNAc concentration to decline by half.</description>
        <time_frame>Day 7</time_frame>
        <population>All subjects received ManNAc</population>
        <group_list>
          <group group_id="O1">
            <title>ManNAc: Cohort A</title>
            <description>ManNAc 3 g twice daily (6 g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>ManNAc: Cohort B</title>
            <description>ManNAc 6 g twice daily (12 g/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t Â½) for ManNAc</title>
          <description>The amount of time it takes for plasma ManNAc concentration to decline by half.</description>
          <population>All subjects received ManNAc</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.3"/>
                    <measurement group_id="O2" value="2.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Curve (AUClast) of Plasma Neu5Ac (Baseline-adjusted)</title>
        <description>The mean area under the plasma Neu5Ac concentration-versus time curve from time 0 (dosing) to the time of last quantifiable concentration.</description>
        <time_frame>Day 7</time_frame>
        <population>All subjects received ManNAc</population>
        <group_list>
          <group group_id="O1">
            <title>ManNAc: Cohort A</title>
            <description>ManNAc 3 g twice daily (6 g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>ManNAc: Cohort B</title>
            <description>ManNAc 6 g twice daily (12 g/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Curve (AUClast) of Plasma Neu5Ac (Baseline-adjusted)</title>
          <description>The mean area under the plasma Neu5Ac concentration-versus time curve from time 0 (dosing) to the time of last quantifiable concentration.</description>
          <population>All subjects received ManNAc</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4206" spread="1352"/>
                    <measurement group_id="O2" value="5175" spread="1421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Neu5Ac (Baseline-adjusted)</title>
        <description>The maximum (or peak) plasma Neu5Ac concentration that the drug achieves in the body after the drug has been administrated.</description>
        <time_frame>Day 7</time_frame>
        <population>All subjects received ManNAc</population>
        <group_list>
          <group group_id="O1">
            <title>ManNAc: Cohort A</title>
            <description>ManNAc 3 g twice daily (6 g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>ManNAc: Cohort B</title>
            <description>ManNAc 6 g twice daily (12 g/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Neu5Ac (Baseline-adjusted)</title>
          <description>The maximum (or peak) plasma Neu5Ac concentration that the drug achieves in the body after the drug has been administrated.</description>
          <population>All subjects received ManNAc</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469" spread="35.1"/>
                    <measurement group_id="O2" value="620" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Time to Cmax (Tmax) for Neu5Ac</title>
        <description>The time taken to achieve the maximum observed plasma concentration for Neu5Ac.</description>
        <time_frame>Day 7</time_frame>
        <population>All subjects received ManNAc</population>
        <group_list>
          <group group_id="O1">
            <title>ManNAc: Cohort A</title>
            <description>ManNAc 3 g twice daily (6 g/day) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>ManNAc: Cohort B</title>
            <description>ManNAc 6 g twice daily (12 g/day)</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Cmax (Tmax) for Neu5Ac</title>
          <description>The time taken to achieve the maximum observed plasma concentration for Neu5Ac.</description>
          <population>All subjects received ManNAc</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="4.1"/>
                    <measurement group_id="O2" value="6.0" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ManNAc 3 g - 7 Days</title>
          <description>Subjects who received oral ManNAc 3 g twice daily (6 g/day) for the first 7 days.</description>
        </group>
        <group group_id="E2">
          <title>ManNAc 6 g - 7 Days</title>
          <description>Subjects who received oral ManNAc 6 g twice daily (12 g/day) for the first 7 days.</description>
        </group>
        <group group_id="E3">
          <title>ManNAc 6 g - Day 8 to 30 Months</title>
          <description>All subjects received oral ManNAc 6 g twice daily (12 g/day) from day 8 to the end of the study at 30 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyshidrotic eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carrillo, Nuria</name_or_title>
      <organization>National Human Genome Research Institute</organization>
      <phone>+1 301 402 2324</phone>
      <email>nuria.carrillo@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

